Pulmonx (LUNG) Research & Development (2019 - 2025)

Pulmonx (LUNG) has 7 years of Research & Development data on file, last reported at $4.8 million in Q3 2025.

• On a quarterly basis, Research & Development rose 29.43% year-over-year to $4.8 million in Q3 2025; TTM through Sep 2025 was $18.9 million, a 8.27% increase from a year earlier, with the FY2024 full-year figure at $17.6 million, down 2.82% from the prior year.
• Research & Development for Q3 2025 stood at $4.8 million, down from $5.3 million in the prior quarter.
• Over the last five years, Research & Development for LUNG reached as high as $5.7 million in Q2 2023 and fell as low as $2.8 million in Q3 2021.
• Historically, Research & Development has averaged $4.2 million across 5 years, with a median of $4.0 million in 2024.
• Across the five-year window, Research & Development surged 145.86% in 2021 and fell 11.28% in 2024, its largest moves.
• Year by year, Research & Development stood at $3.7 million in 2021, then advanced by 5.26% to $3.9 million in 2022, then slipped by 0.18% to $3.9 million in 2023, then advanced by 2.7% to $4.0 million in 2024, then increased by 21.12% to $4.8 million in 2025.
• Per Business Quant data, the three most recent Research & Development figures were $4.8 million in Q3 2025, $5.3 million in Q2 2025, and $4.8 million in Q1 2025.